Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

2025 revenue of $37.1 million, up 4% year-over-year, and 71% Full-year gross margins Enhanced Balance Sheet Flexibility with an Additional $2.5 million Proceeds from Amended Credit Facility in November Implemented Strategic Workforce and Cost Reduction Program in Q4 to Accelerate Timing to Cash Flow Breakeven in 2026 Ongoing Interactive Discussions with FDA to Determine Content and Timing of New De Novo Application for DrugSorb™ -ATR PRINCETON, N.J., March 25, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the fourth quarter and full year ended December 31, 2025, and recent business highlights.

CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026

PRINCETON, N.J., March 19, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced three major developments at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) this week in Brussels, Belgium - one of the largest global conferences dedicated to critical care medicine:  The introduction of HotSwap™ by CytoSorbents – The New CytoSorb exchange system The renewal of its long-standing partnership with Aferetica Srl in Italy, and New clinical data reinforcing the growing body of evidence supporting CytoSorb® therapy CytoSorbents Launches HotSwap™ to Simplify and Optimize Therapy CytoSorbents announced the immediate availability of HotSwap™, an innovative solution designed to enable rapid, seamless exchange of CytoSorb adsorbers during the treatment of critically-ill patients.

CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results and Business Update

Fourth quarter and Full-Year 2025 revenue are expected to be approximately $9.2 million and $37.0 million, respectively, with expected Q4 gross margins in the range of 73% to 75% DrugSorb®-ATR De Novo Pre-Submission M eeting scheduled with the FDA this month, with anticipated De Novo Application filing this quarter and  regulatory decision in mid-2026 Results of the pivotal STAR-T study for DrugSorb ® -ATR have recently been accepted for publication in a top cardiac surgery journal Management will host in-person investor meetings in San Francisco during J.P. Morgan Healthcare Conference week PRINCETON, N.J.

CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025

PRINCETON, N.J. , Dec. 10, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that Dr. Phillip Chan, CEO, and Peter J.